Objective: Motivational deficits are prevalent in patients with schizophrenia, persist despite antipsychotic treatment, and predict long-term outcomes. Evidence suggests that patients with greater amotivation have smaller ventral striatum (VS) volumes. We wished to replicate this finding in a sample of older, chronically medicated patients with schizophrenia. Using structural imaging and positron emission tomography, we examined whether amotivation uniquely predicted VS volumes beyond the effects of striatal dopamine D 2/3 receptor (D 2/3 R) blockade by antipsychotics.
While several studies have focused on the cortex, few studies have specifically examined the relationship between VS morphology and amotivation in patients with schizophrenia. Examination of the VS as a substrate for amotivation in schizophrenia is particularly relevant given its proposed role in regulating motivated behaviour. 10, 13 To our knowledge, only 1 study by Roth and colleagues has specifically explored this relationship.
14 They observed that patients (n = 23) with more severe amotivation demonstrated reduced grey matter (GM) volumes in the right VS. While several lines of preclinical evidence suggest that reduced dopamine (DA) functioning at D 2/3 receptors (D 2/3 Rs) in the VS increases amotivation, 7, 15, 16 there have been mixed observations in schizophrenia. In untreated patients, greater amotivation has been associated with lower endogenous DA at D 2/3 R in the VS (r 2 = .47, P = .001). 17 However, treatment with antipsychotics, which antagonize D 2/3 R, does not seem to significantly worsen nor improve motivational deficits in patients with schizophrenia. 18 Consistently, several studies suggest that occupancy of striatal D 2/3 R by antipsychotics is related to improvements in positive symptoms, with no relationship to negative symptoms. [19] [20] [21] [22] In a sample of older, chronically treated patients, estimated antipsychotic occupancy of D 2/3 R in the VS was not found to be related to amotivation. 23 Reducing the dose of antipsychotics in the same sample failed to significantly improve motivation. Thus, the functional status of striatal D 2/3 R in motivated behaviour may be different in patients with schizophrenia who are treated acutely versus chronically with antipsychotics.
We wished to replicate previous findings of a relationship between reduced VS volumes and greater amotivation in a sample of older, chronically medicated patients with schizophrenia. This would help inform whether reduced VS volumes are a correlate of amotivation across the lifespan. We wanted to examine this relationship while controlling for estimated striatal D 2/3 R occupancy by antipsychotic drugs, evaluated using positron emission tomography (PET). This would help elucidate whether antipsychotic D 2/3 R blockade modulates the relationship between motivation and brain morphology. Notably, estimated striatal D 2/3 R occupancy provides a more biologically and clinically relevant correlate of antipsychotic action in the brain than does dose. 24 Thus, above and beyond the effects of antipsychotic-induced striatal D 2/3 R blockade, we hypothesized that levels of amotivation would be negatively correlated with VS volume.
2 | METHODS
| Participants
This is an extension of a previous study; the methods and main results have been published elsewhere. 25 Patients were recruited based on the following: (1) having a DSM-IV diagnosis of schizophrenia or schizoaffective disorder, confirmed by the Structured Clinical
Interview for DSM-IV-TR Axis I Disorders, 26 (2) being ≥50 years old, Key points
• We replicate and extend the finding that amotivation is associated with reduced ventral striatum volumes in an elderly medicated sample of patients with schizophrenia.
• This relationship was independent of estimated antipsychotic occupancy of striatal dopamine D 2/3
receptors measured with positron emission tomography.
• Consistent with previous findings, the association between amotivation and ventral striatal volume was stronger in the right hemisphere.
These subjects come from a previously published study examining D 32, 39 This source of error is unlikely to introduce a systematic bias across subjects. 
| Magnetic resonance imaging

| Subcortical volume analyses
The Multiple Automatically Generated Templates (MAGeT-Brain) algorithm 40, 41 was used to provide fully automated segmentation of striatal subdivisions in participants' native space. 42 The MAGeT-Brain algorithm is a modified multiatlas segmentation technique, which uses a limited number of high-quality manually segmented atlases as an input to reduce bias and enhance segmentation accuracy. The
MAGeT-Brain propagates atlas segmentations to a template library, formed from a subset of target images, via transformations estimated by nonlinear image registration. The resulting segmentations are then propagated to each target image and fused using a label fusion method. A subset of subjects (n = 21) was used as template libraries through which the final segmentation was bootstrapped, chosen based on representative subject characteristics. 43 Volumes (mm 3 ) were extracted bilaterally from the VS and the whole striatum. Figure S1 in the Supporting Information demonstrates the results of the automatic striatal subdivision labelling in a single subject.
| Total brain volume analysis
The procedure for total brain volume (TBV) analysis has been published elsewhere. 44 Total brain volume was obtained using the brain extraction based on a nonlocal segmentation technique method. 45 This includes cerebrospinal fluid (in the ventricles, cerebellar cistern, deep sulci, along the surface of the brain, and brainstem), the brainstem, and cerebellar white matter and GM in the brain mask, while excluding the skull, skin, fat, muscles, dura, eyes, bone, exterior blood vessels, and exterior nerves.
| Symptom assessments
Clinical status was evaluated using the Positive and Negative Syndrome Scale (PANSS), 46 and symptom scores were evaluated using consensus-defined factors. 47 Given the burgeoning evidence for a 2-factor structure of negative symptoms in schizophrenia, 48, 49 we calculated 2 additional scores to evaluate amotivation and expressive deficits separately. Specifically, a social amotivation score (amotivation factor) was derived by summing the following items from the PANSS:
. 50 A diminished expression score (diminished expression factor) was calculated by summing the following items from the PANSS: blunted affect, poor rapport, lack of spontaneity and flow of conversation, and motor retardation. 50 Higher scores on each of these measures reflect greater negative symptom severity. Cognitive functioning was assessed using the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS). 51 Given this previous literature elucidating the factor analytic structure of PANSS negative symptoms, we did not explore how modifications (ie, removing certain items) to factor scores could affect our results. as the third step. Several groups, including ourselves, have demonstrated that while amotivation and cognition are distinct constructs, they have some shared variance. 5 Thus, we wished to explore whether the relationship between amotivation and VS volume would persist considering the potential variance in amotivation accounted for by cognition. A subset of the sample also had cognitive scores available.
| Statistical analysis
For these subjects, we recomputed our models including global cognition in the second step to determine whether the relationship of interest would hold while controlling for this variable as well. In Table S1 , we present the correlations between all the variables included in our multivariate regression models. In our current sample, there is a trend correlation (P = .08) between amotivation and RBANS total scores.
Moreover, D 2/3 R occupancy is negatively correlated with VS volumes and TBV. While this is consistent with some (but not all) findings that antipsychotic exposure is related to reductions in both striatal volume and TBV, 52,53 our sample is not poised to directly address causality regarding the issue of how antipsychotic exposure may change brain morphology in schizophrenia.
We conducted several analyses to explore the specificity of the amotivation-VS volume relationship. Specifically, we recomputed the above analyses with total striatal volume as the dependent variable. In addition, in separate models, we explored whether another negative symptom, namely, diminished expression, would be related to VS volumes.
The alpha level of significance for all our a priori hypotheses and confirmatory analyses was set at P < .05 (2-tailed).
| RESULTS
Participant characteristics are detailed in Table 1 . In our multivariate regression model (see Table 2 ), age, gender, TBV, and striatal D 2/3 R occupancy together explained 47% of the variance in right VS volumes.
Considering these variables, in addition to positive and depression symptoms, amotivation significantly explained an additional 8% of the variance in right VS volumes. Thus, over and above the contribution of participant characteristics, striatal D 2/3 R occupancy, positive symptoms, depression symptoms, and levels of amotivation were negatively associated with right VS volumes (see Figure 1A) . Similarly, in the left VS, amotivation significantly explained an additional 6% of the variance above and beyond that explained by the other variables (seeTable 2 and Figure 1B ). Since years of education and the number of cigarettes smoked per day could theoretically influence the relationship between symptoms and VS volume, we explored including these variables as an additional step in our multivariate regression model (see Table S2 ).
We wished to explore whether amotivation could account for a significant proportion of the variance in VS volumes after considering global cognitive functioning assessed with total RBANS scores. Five participants did not provide total RBANS scores. After considering global cognitive functioning, amotivation continued to explain a significant proportion (9%) of the variance in right VS volumes, but not left VS volumes (see Table 3 ). Since there could be potential interactions between cognition and symptomatology on brain morphology, we explored whether amotivation could continue to account for a significant proportion of the variance in right VS volumes after the inclusion of cognition * symptom interaction terms. Amotivation continued to explain a significant proportion (9%) of the variance in right VS volumes, but not left VS volumes, after considering these potential interactions (see Table 4 ).
We explored the specificity of our findings to amotivation, rather than to other negative symptoms. We constructed separate regression models using diminished expression scores instead of amotivation scores as the final predictive step (these negative symptoms were positively correlated with each other: r = .75, P < .0001). Notably, 
| DISCUSSION
We found that amotivation in older, chronically medicated patients with schizophrenia is significantly related to smaller VS volumes. This relationship persisted after considering several a priori variables often associated with amotivation and brain morphology. These findings are consistent with the theorized role of the VS in motivation 16 and replicate and extend previous findings. 14 Besides including estimated striatal D 2/3 R occupancy, our study has several strengths that serve to extend previously published work.
First, our study included additional covariates--positive symptom severity and cognition--and found the relationship between amotivation and VS volumes to hold even after statistically controlling for these. Second, our study examined the specificity of this relationship. We failed to find an association between negative symptoms in general and VS volumes. Rather, the relationship was specific to amotivation. Furthermore, the relationship between amotivation and striatal morphology was specific to the VS, as a significant association was not observed with total striatal volumes. Collectively, this study provides a more comprehensive approach to the question of whether amotivation is related to VS morphology in schizophrenia, suggesting a specific relationship. An additional strength is that the patients in our sample were clinically stable and had received the same dose of medication monotherapy for the last 6 months.
Several functional MRI studies have linked amotivation in schizophrenia with reduced activation of the VS. [54] [55] [56] Our findings raise the possibility that previously reported VS hypoactivation may be the result of, or related to, reduced VS volume. The neurofunctional Table S3 , we provide our main analyses of interest using chlorpromazine equiva- 
